Grant Details
Grant Number: |
7R29CA067285-06 Interpret this number |
Primary Investigator: |
Moorman, Patricia |
Organization: |
Duke University |
Project Title: |
Medication Use & Breast Cancer in a Biracial Population |
Fiscal Year: |
2000 |
Abstract
DESCRIPTION: (Adapted from Applicant's Abstract). The objective of this
FIRST award in epidemiology is to examine the role of several commonly used
medications that may either increase (hormones, antidepressants) or decrease
(nonsteroidal anti-inflammatory drugs (NSAIDs), anti-oxidants) the risk of
breast cancer. The proposed studies will utilize the infrastructure
established for a large, population-based, case-control study of breast
cancer in North Carolina, the Carolina Breast Cancer Study (CBCS). The CBCS
will have enrolled 800 cases and 800 controls by the end of its first phase
in spring, 1996, and an additional 1600 participants will be recruited in
its second phase. The study population will have approximately equal
numbers of black and white women, allowing an evaluation of potential racial
differences in the association of these medications and breast cancer risk.
Information on hormone use and anti-oxidant consumption is currently being
collected as part of a comprehensive questionnaire on breast cancer risk
factors. Questions to assess the use of NSAIDs and antidepressants will be
developed and added to the questionnaire used in the second phase of the
CBCS. Analyses of the data will focus on hypotheses derived from
preliminary investigations, including animal studies (i.e., NSAIDs'
protective effect, and the antidepressants' tumor promotion effect) or
questions that have remained unanswered due to temporal considerations
(i.e., the risk of peri- and postmenopausal breast cancer among women who
used oral contraceptives early in their reproductive years, and the risk
among women who used both oral contraceptives and menopausal hormones). The
investigation of the roles these medications play in the development of
breast cancer is important for several reasons. Physicians and patients
should know the potential adverse effects associated with a given therapy so
they can make informed judgments of the benefits versus the risks. Because
millions of women are prescribed hormones and antidepressants each year,
even a model increase in risk could translate into a large number of breast
cancers. For the medications with evidence suggestive of a protect effect,
it is important.
Publications
None